The proposed bill SB1453 seeks to regulate the possession, preparation, production, manufacturing, distribution, sale, and exposure for sale of hemp-derived manufactured impairing cannabinoids in Arizona. It would require individuals or entities to hold a certificate as a medical or recreational marijuana dispensary and obtain approval from the Department of Health Services (DHS) to handle such cannabinoids. The bill defines "hemp-derived manufactured impairing cannabinoids" as any cannabinoid derived from the cannabis plant that is altered chemically to change its molecular structure to another cannabinoid with impairing properties found naturally in hemp. It includes substances like various forms of tetrahydrocannabinol (THC) and excludes non-intoxicating cannabinoids like cannabidiol (CBD).

The bill outlines specific prohibitions, such as the sale or distribution of these cannabinoids outside of Arizona, and imposes restrictions on licensed hemp processors regarding these substances. It also mandates that the DHS regulate these cannabinoids to protect public health and safety, including adopting rules for labeling, warning about health risks, and additional testing requirements. Violations of the laws relating to hemp-derived manufactured impairing cannabinoids would be considered a class 2 misdemeanor, and aggrieved parties could seek damages through private legal action. The DHS would be authorized to use funds from the Medical Marijuana Fund and the Smart and Safe Arizona Fund to implement and regulate these cannabinoids, and the Attorney General could use funds to investigate and take action related to their sale, marketing, and distribution.